

1 **Pseudotemporal ordering of spatial lymphoid tissue microenvironment**
2 **profiles trails Unclassified DLBCL at the periphery of the follicle**

3

4 **Claudio Tripodo^{1,2}, Giorgio Bertolazzi^{1,3}, Valeria Cancila¹, Gaia Morello¹, Emilio Iannitto^{*1,4}**

5

6 ¹ Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy

7 ² Histopathology Unit, The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy

8 ³ Department of Statistical Sciences, University of Palermo, Palermo, Italy

9 ⁴ Department of Oncology, Hematology and Bone Marrow Transplants Unit La Maddalena, Palermo, Italy

10 * These authors contributed equally

11

12

13 **Corresponding author:**

14 Prof. Claudio Tripodo

15 Claudio.tripodo@unipa.it

16

17 **Running title:** A peri-follicular origin for Unclassified DLBCL?

18 **Keywords:** Digital spatial profiling; lymphoid tissue microenvironment; pseudotemporal ordering;
19 Diffuse Large B cell Lymphoma; Cell-of-origin

20

21 The Authors have no conflict of interest to disclose

22

23 **Abstract**

24 We have established a pseudotemporal ordering for the transcriptional signatures of distinct
25 microregions within reactive lymphoid tissues, namely germinal center dark zones (DZ), germinal
26 center light zones (LZ), and peri-follicular areas (Peri). By utilizing this pseudotime trajectory
27 derived from the functional microenvironments of DZ, LZ, and Peri, we have ordered the
28 transcriptomes of Diffuse Large B-cell Lymphoma cases. The apex of the resulting pseudotemporal
29 trajectory, which is characterized by enrichment of molecular programs fronted by TNFR signaling
30 and inhibitory immune checkpoint overexpression, intercepts a discrete peri-follicular biology. This
31 observation is associated with DLBCL cases that are enriched in the Unclassified/type-3 COO
32 category, raising questions about the potential extra-GC microenvironment imprint of this peculiar
33 group of cases. This report offers a thought-provoking perspective on the relationship between
34 transcriptional profiling of functional lymphoid tissue microenvironments and the evolving concept
35 of the cell of origin in Diffuse Large B-cell Lymphomas.

36

37 Diffuse large B-cell lymphomas (DLBCL) are phenotypically and genetically heterogeneous.
38 Applying a classification algorithm to the gene expression profile of DLBCLs segregates the cases
39 into two major subgroups¹. Germinal Center B Cell-like (GCB) DLBCL subgroup shows a high level
40 of expression of genes characteristic of physiological germinal center (GC) reaction molecular
41 programs. Another DLBCL subgroup labelled Activated B Cell-like (ABC) expresses genes typical
42 of mitogenically-activated B-cells, is enriched in plasma cell-related programs, and regarded as
43 embodying post-GC dynamics. A third subgroup of DLBCL cases is left out from the GCB/ABC
44 dichotomy, which does not express either set of genes at a high level and is accordingly named
45 Unclassified or Type-3². Based on the transcriptional profile similarity, GCB and ABC DLBCL are
46 considered frozen in or stemming from a cell of origin (COO) at a different stage of the functional
47 modulation pathway engaging B-cells in their GC journey towards Plasma cells or memory B³. At
48 difference, the Unclassified/Type-3 DLBCL group has been considered as possibly consisting of
49 more than one type of DLBCL and populated mainly by borderline cases not assigned by the
50 clustering algorithm, yet actually belonging to the ABC or GCB group². Several subsequent
51 studies, applying different profiling platforms and classification algorithms, reproduced this
52 molecular DLBCL tripartition, with the GCB representing the largest group (46-58%), followed by
53 ABC (27-40%) and Unclassified/Type-3 (10-22%)⁴⁻⁷. Retrospective studies reported that GCB
54 DLBCL show a significantly better overall survival (OS) curve than ABC; conversely, the
55 Unclassified/Type-3 group outcome varies widely among different retrospective series, showing an
56 OS curve comparable to that of ABC or GCB DLBCL or lying in between⁴⁻⁷. Of note, in two large
57 prospective series, each including over a thousand patients, the Unclassified/Type-3 COO DLBCLs
58 showed an outcome comparable to that of the ABC group^{8,9}. Recently, the genetic heterogeneity
59 and complexity underlying the COO expression profile have been partially elucidated.
60 Comprehensive genomic analysis with different platforms led to the genetic subtype classification
61 of DLBCLs^{6,10,11}. With the caveat that nearly half of cases remained unclassified^{6,12}, the genetic
62 subtype classification of DLBCL highlighted that each of the three DLBCL COO gene expression
63 subgroups included multiple genetic profiles. In particular, the Unclassified/Type-3 COO came out
64 to be enriched for the BN2 genetic subtype that accounted for over one-third of cases, and

65 comprised also cases belonging to ST2, EZB, MCD, A53 genetic clusters¹². BN2 DLBCL are
66 characterized by mutations that activate NOTCH2 or inactivate the NOTCH antagonist SPEN,
67 frequently co-occurring with BCL6 translocations. Genetic aberrations targeting regulators of the
68 NF- κ B pathway are another prominent feature of BN2 DLBCL. Mutations targeting components of
69 the BCR-dependent NF- κ B pathway (PRKCB, BCL10, TNFAIP3, TNIP1) occur in over 50% of
70 cases predicting that these tumours rely on B-cell receptor-dependent NF- κ B activation and could
71 be vulnerable to antagonists of B-cell receptor signalling⁶. The genomic profile of the BN2 cluster
72 closely reminds that of Marginal Zone Lymphoma (MZL) and transformed MZL. All BN2 cases
73 were confirmed to display a canonical DLBCL histological picture, suggesting that the
74 Unclassified/Type-3 COO, besides misclassified BCL and GCB cases, may host a distinct subset
75 of DLBCL⁶. However, whether the Unclassified/Type-3 group is merely the wastebasket of gene
76 expression profile (GEP) classification algorithms or the profile of DLBCL originating from discrete
77 functional differentiation stages and microenvironmental settings has not been elucidated.

78 We have exploited the spatial transcriptional profiling (1824 genes, cancer transcriptome atlas
79 panel) of 15 microregions (Regions of Interest, ROIs) relative to GC dark zone (DZ, n=5) and light
80 zone (LZ, n=5) microenvironment and peri-follicular (Peri n=5) areas. We used a pseudotime
81 algorithm called PhenoPath¹³ to learn about the biological progression that characterizes the ROIs
82 of interest. In the context of single-cell analysis, pseudo time is a computational construct that is
83 used to order cells along a temporal trajectory, based on the similarity of their gene expression
84 profiles. Pseudo time analysis aims to capture the temporal ordering of cells based on the
85 expression changes of key genes, without directly measuring the time point at which the cells were
86 collected. Pseudo time analysis can help to reveal the cellular processes that are active during
87 different stages of development or differentiation, and can provide insights into the regulatory
88 networks that govern these processes. The recent development of a pseudotime algorithm
89 calibrated for bulk RNA-seq data¹³ allowed us to extract the latent temporal information from the
90 digital spatial profiling ROIs. Using PhenoPath we estimated the pseudotemporal values from the
91 bulk gene-expression matrix (supplementary table 1). Based on the pseudotime estimation, we
92 obtained a pseudotemporal ordering of the individual ROIs. The pseudotime trajectory extended

93 from DZ towards Peri regions, showing a clear association between pseudotemporal order and the
94 spatial and functional ROI features (Figure 1A). Pseudotemporal ordering of digital spatial profiling
95 ROIs enabled the identification of a pseudotime-associated gene signature composed of 184
96 genes significantly correlated with pseudotime (68 positively and 116 negatively) (Figure 1B,
97 Supplementary Table 1). The genes positively associated with pseudotime were mostly enriched in
98 TNF signaling pathway genes (i.e. *NFRSF14*, *TNFRSF25*, *TNFRSF1A*, *TNFRSF1B*) and in genes
99 involved in the negative regulation of T-cell activation (i.e. *CD274*, *VSIR*, *LAG3*, *IDO1* –
100 Supplementary Table 2) while those inversely associated with pseudotime were enriched in cell
101 proliferation, DNA damage repair, and B-cell receptor signaling programs (Supplementary Table 2-
102 3). In the attempt to investigate the effects of the pseudotime trajectory derived from the
103 transcriptional profiling of functional microenvironments of a reactive lymphoid tissue on the
104 ordering of DLBCL transcriptomes, we applied the 184-genes pseudotime signature to four
105 independent gene expression-profiled DLBCL cohorts⁴⁻⁷ (Figure 2A-D). The four cohorts
106 characterized by different case selection criteria and gene expression profiling technologies
107 (Illumina, Affymetrix), displayed a generally conserved significance of the GCB vs ABC comparison
108 in terms of OS (Supplementary Figure 1A-D). At odds, the fractions and prognostic behavior of
109 Unclassified/Type-3 COO clusters in the four series were quite different (Supplementary Figure 1A-
110 D), suggesting that this group of DLBCL might encompass a remarkable biological heterogeneity.
111 By applying the pseudotime-associated microenvironment signature according to the tertile
112 distribution of the cumulative expression of genes negatively and positively associated with
113 pseudotime, DLBCL cases of the four cohorts displayed a common trend towards the enrichment
114 of GCB cases in the *low-pseudotime* tertile (Figure 2E) a rather heterogeneous distribution of ABC
115 cases, and a clear enrichment of Unclassified/Type-3 COO cases in the *high-pseudotime* tertile
116 (Figure 2E). Consistently, the distribution of DLBCL genetic subgroups according to Schmitz
117 across the low-, intermediate-, and high-pseudotime tertiles showed significant enrichment of EZB
118 and other GCB genetics in the low-pseudotime group (Figure 2F, Supplementary Table 4). At the
119 same time, BN2 was slightly enriched in the intermediate-pseudotime group, and other
120 Unclassified genetics were detected across the three pseudotime categories, further indicating

121 their mirroring of divergent biologies. We further explored if the pseudotime tertile hierarchy could
122 rank DLBCL in groups with different prognosis. This hypothesis was tested in the series by Sha et
123 al. (GSE117556)⁷, which offers distinctive features that are relevant to this extent: 1) a large
124 prospective clinical data-set of 928 18-years or older DLBCL patients, with a centralized gene
125 expression profiling and pathological review, eligible for anthracycline-based treatment; 2) 30
126 months Progression-Free Survival (PFS) in line with the best results of the recent phase 3 trials on
127 DLBCL; 3) COO classification refined retrospectively with the same method, taking advantage of
128 higher quality samples and improved data normalization over the complete data-set⁷. Most
129 importantly, in this large series, the COO classification failed to identify groups with significantly
130 different prognosis (Supplementary Figure 1E-F). The application of trichotomization of the series
131 according to pseudotemporal scoring revealed significant prognostic differences between
132 pseudotime-low and -high tertiles, with cases displaying high pseudotime ordering faring
133 significantly better in terms of OS and PFS (Figure 2G, Supplementary Table 5). The different
134 prognostic performance of COO and pseudotemporal ordering in this setting suggests that the
135 transcriptional modulations represented in the spatial profiling of diverse GC and extra-follicular
136 microregions may adequately cope with the wide continuum of DLBCL.

137 Our results also demonstrate that the apex of the pseudotemporal trajectory resulting from spatial
138 profiling intercepts a discrete peri-follicular biology characterized by enrichment of molecular
139 programs fronted by TNFR signaling and inhibitory immune checkpoint overexpression and
140 corresponding to cases enriched in the Unclassified/type-3 COO category, opening an issue
141 regarding the potential extra-GC imprint of this heterogeneous group of cases. Moreover, an
142 accurate biomolecular characterization of this hitherto neglected subset of DLBCL might pave the
143 way for deciphering their biological and prognostic determinants.

144

145 **References**

146 1 Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A *et al.* Distinct types of diffuse
147 large B-cell lymphoma identified by gene expression profiling. 2000www.nature.com.

- 148 2 Rosenwald A, Osenwald R, Eorge G, Right W, Ing W, Han CC *et al.* THE USE OF MOLECULAR
149 PROFILING TO PREDICT SURVIVAL AFTER CHEMOTHERAPY FOR DIFFUSE LARGE-B-
150 CELL LYMPHOMA A BSTRACT Background The survival of patients with diffuse.
151 2002<http://www.nejm.org>.
- 152 3 Pasqualucci L. Molecular pathogenesis of germinal center-derived B cell lymphomas. *Immunol*
153 *Rev.* 2019; **288**: 240–261.
- 154 4 Barrans SL, Crouch S, Care MA, Worrillow L, Smith A, Patmore R *et al.* Whole genome
155 expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-
156 cell lymphoma and predict clinical outcome. *Br J Haematol* 2012; **159**: 441–453.
- 157 5 Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H *et al.* Stromal Gene Signatures in Large-
158 B-Cell Lymphomas. *New England Journal of Medicine* 2008; **359**: 2313–2323.
- 159 6 Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ *et al.* Genetics and
160 Pathogenesis of Diffuse Large B-Cell Lymphoma. *New England Journal of Medicine* 2018; **378**:
161 1396–1407.
- 162 7 Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T *et al.* Molecular High-Grade B-
163 Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. *J*
164 *Clin Oncol* 2018; **37**: 202–212.
- 165 8 Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U *et al.* Gene-expression
166 profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell
167 lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. *Lancet Oncol* 2019; **20**: 649–
168 662.
- 169 9 Vitolo U, Trněný MT, Belada D, Burke JM, Carella AM, Chua N *et al.* JOURNAL OF CLINICAL
170 ONCOLOGY Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and
171 Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2017; **35**:
172 3529–3537.
- 173 10 Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA *et al.* Molecular subtypes of
174 diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and
175 outcomes. *Nat Med* 2018; **24**: 679–690.
- 176 11 Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S *et al.* Prognostic
177 Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene
178 Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. *J Clin Oncol.* 2015 Sep
179 10;33(26):2848-56.
- 180 12 Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM *et al.* A Probabilistic
181 Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic
182 Implications. *Cancer Cell* 2020; 37: 551-568.e14
- 183 13 Campbell KR, Yau C. Uncovering pseudotemporal trajectories with covariates from single cell
184 and bulk expression data. doi:10.1038/s41467-018-04696-6.
- 185 14 L’Imperio V, Morello G, Vegliante MC, Cancila V, Bertolazzi G, Mazzara S *et al.* Spatial
186 transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79 mutants-enriched
187 diffuse large B-cell lymphomas. *Eur J Immunol* 2022; 52: 1350–1361.

188

189

190 **Figure Legends**


191 **Figure 1: A**, Two-dimensional principal component projection produces a trajectory among DZ, LZ,
192 and Peri ROIs. The color gradient of points reflects the pseudotime estimated values. **B**,
193 Expression heatmap of the 184 genes significantly correlated with the pseudotime over 15 ROIs.

194 The 15 ROIs (columns) are ordered according to the pseudotime estimation.

195 **Figure 2: A-D**, Expression heatmap of the 184 pseudotime-related genes. The DLBCL cases
196 (columns) are ordered according to their pseudotime-related score (see methods). Three
197 pseudotime groups have been identified by applying the tertile separation on pseudotime-related
198 scores (i.e., low, intermediate, and high pseudotime groups). **E**, Jaccard similarity index between
199 COO and pseudotime groups over DLBCL datasets. Unclassified cases strongly enrich all the
200 high-pseudotime groups. While GCB cases enrich all the low-pseudotime groups (Fisher p-values
201 are shown in the table). **F**, Proportions of pseudotime categories over genetic subtype groups. The
202 Fisher exact test has been applied to evaluate the association between genetic subtypes and
203 pseudotime categories (Suppl. Table 4). **G**, Survival analysis on DLBCL cases from Sha et al.
204 dataset. Patients were divided into three groups according to the tertiles of their pseudotime-
205 related scores (i.e., low, intermediate, and high pseudotime groups).

Figure 1

A



B




Figure 2

